Cardiac Amyloidosis Global Market Report 2025

The cardiac amyloidosis market size has grown strongly in recent years. It will grow from $5.26 billion in 2024 to $5.75 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the increasing prevalence of amyloidosis-related conditions, genetic mutations, heightened awareness, a rising number of transthyretin amyloidosis cases, and the growing geriatric population.

The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.1 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth during the forecast period can be attributed to higher diagnosis rates, government support and initiatives, the rising prevalence of genetic mutations, and patient assistance programs. Key trends expected in this period include the development of new therapies such as vutrisiran, expanding research in gene therapy, a focus on precision medicine, advancements in diagnostic technologies, and the emergence of novel treatments.

The rising geriatric population is expected to drive the growth of the cardiac amyloidosis market in the coming years. The geriatric population refers to individuals aged 65 and older who often require specialized healthcare due to age-related conditions. The steady increase in this population is driven by rising life expectancy, advancements in medical care, and declining birth rates. Since aging is a significant risk factor for amyloid protein accumulation in the heart, the growing number of older adults contributes to the increasing prevalence of cardiac amyloidosis. For example, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, the expanding geriatric demographic is expected to fuel the growth of the cardiac amyloidosis market.

Leading companies in the cardiac amyloidosis market are focusing on technological advancements, such as artificial intelligence (AI)-based diagnostic tools, to improve early disease detection and enhance clinical outcomes. AI-powered, software-only medical devices can analyze echocardiographic images and identify signs of cardiac amyloidosis without the need for additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-driven clinical tool for early cardiac amyloidosis detection. It is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using AI, EchoGo Amyloidosis analyzes echocardiograms from a single clip, enabling earlier detection before the disease progresses undetected.

In January 2024, Ultromics Ltd. partnered with Pfizer Inc. to further develop its Echo AI algorithm for cardiac amyloidosis detection. This partnership aims to enhance diagnostic accuracy and improve patient outcomes. Pfizer Inc. is a US-based pharmaceutical company specializing in innovative medicines, including treatments for cardiac amyloidosis, as well as consumer healthcare products.

Major players in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., and Eidos Therapeutics.

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiac amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiac amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiac amyloidosis is a condition characterized by the deposition of abnormal amyloid proteins in the heart tissue, resulting in stiffness and impaired function. This leads to heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are essential for managing symptoms and slowing disease progression.

The primary types of cardiac amyloidosis are light-chain amyloidosis and transthyretin amyloidosis. Light-chain amyloidosis (AL amyloidosis) is a disorder in which misfolded immunoglobulin light chains form amyloid deposits in various organs, including the heart, causing dysfunction and potential organ failure. Treatment options include chemotherapy, surgery, supportive care, stem cell transplantation, and targeted therapy. The disease is primarily managed in hospitals, ambulatory surgical centers, and clinics.

The cardiac amyloidosis market research report is one of a series of new reports that provides cardiac amyloidosis market statistics, including the cardiac amyloidosis industry global market size, regional shares, competitors with the cardiac amyloidosis market share, detailed cardiac amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac amyloidosis industry. This cardiac amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac amyloidosis market consists of revenues earned by entities by providing services such as early diagnosis through imaging and biomarker testing, medication management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac amyloidosis market also includes sales of diagnostic imaging tools, biomarker testing kits, and disease-modifying therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.